Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
Feature|Articles|August 16, 2024
- Pharmaceutical Executive: July/August 2024
- Volume 44
- Issue 7/8
Pharmaceutical Executive: July/August 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive July/August 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 2 years ago
An AI Pulse Checkabout 2 years ago
Divergent Paths: Pharm Exec Profiles Five Recent Drug Launchesabout 2 years ago
A Promising Option: Exxuaabout 2 years ago
Opening the Door: Omvohabout 2 years ago
'Marked’ for Stardom?: Truqapabout 2 years ago
Branching Off: Wegovyabout 2 years ago
A Formidable First: Winrevairabout 2 years ago
The Future of Launch Excellence is Generative AIabout 2 years ago
From Potential to Value: Carving a Slice of the CGT ‘PIE'about 2 years ago
Big Bets, Bold StepsAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Rebuilding Clinical Data Workflows for the AI Era
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5